CALLPFEabout 1 month ago11.4Kviews

Pfizer: capacity is the whole story from here

Demand is established and supply is not. The next leg is decided by fill-finish capacity and payer coverage, which are logistics problems rather than scientific ones.

Fatima Al-Hariri@fatima_alhariri

Evidence · 4 cards

The case

Pfizer: capacity is the whole story from here

Demand is established and supply is not. The next leg is decided by fill-finish capacity and payer coverage, which are logistics problems rather than scientific ones.

The edge

The Street says

Consensus models the cycle turning in the second half
Sell-side target clusters within 8% of spotAuto

I say

The turn already happened in order intake two quarters ago
My number is 14% above the street on the out yearCreator est.

Path to target

Entry: 27.09Auto
Out-year EPS: +18% vs consensusCreator est.
Exit multiple: 22x, in line with the last cycle peakCreator est.
= Target: 30.37Creator est.

Catalyst timeline

JUL 18, 2026 · PAST
Q results, margin guide reiterated
AUG 12, 2026 · PAST
Analyst day, capex framework updated
SEP 11, 2026
Next print, the number that decides this

Unlock the full report

The locked call and the disclosures stay visible. The research body unlocks with purchase or subscription.

Fact-checked claims stay on the record
Platform fee is shown as its own line at checkout (10%)
Call block and disclosures remain free to read

Already subscribed? Log in

Discussion · 3

Pauline VidalAUG 8

Finally someone put numbers on this. The comp table did more work for me than the narrative did. How much does this depend on the macro cooperating?

Omri ShakedAUG 7

This is the second-order point everyone skips. The exclusivity window is the part the market keeps mispricing. Curious whether you would still size it the same at a higher entry.

Noa BergmanAUG 6

I think the setup matters more than the thesis here. The regulatory ceiling being quantified changes the model, not just the headline. Any view on how the read-across affects the rest of the group?